Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes

被引:0
|
作者
Jian Zang
Chen Li
Man Xu
Wanni Xu
Xiaowei Kang
Jianhua Wang
Shanquan Luo
Mei Shi
机构
[1] xijing Hospital,Department of Radiation Oncology
[2] Fourth Military Medical University,Department of Health Statistics, Faculty of Preventative Medicine
[3] Fourth Military Medical University,Department of radiology
[4] xijing hospital,State key laboratory of cancer biology and department of pathology
[5] Fourth Military Medical University,undefined
[6] Fourth Military Medical University,undefined
来源
Scientific Reports | / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Given the potentially distinctive histological variations in northwest of China, the aim of current study was to compare the efficacy of induction chemotherapy plus concurrent chemoradiotherapy (IC + CCRT) with concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients with different histological types. A total of 301 patients were included in this study. Patients were classified in two cohorts according to the 2005 WHO World Health Organization histological classification: WHO type IIa group and WHO type IIb group. The Kaplan-Meier method was used to detect the efficacy between IC + CCRT and CCRT in two WHO types cohorts. Propensity score matching method was adopted to balance the baseline covariate and eliminate potential selection bias. On propensity matched analyses, IC + CCRT was found to produce better 3-year DMFS and OS than CCRT in WHO type IIa cohort (DMFS, 76.2% vs. 42.2%, p = 0.029; OS, 78.3% vs. 65.5%, p = 0.027). For WHO type IIb cohort, IC + CCRT was associated with a better 3-year OS (87.4% vs. 77.9%, p = 0.029) and a trend of better 3-year DMFS (85.9% vs. 76%, p = 0.162) compared with CCRT. IC + CCRT was benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes.
引用
收藏
相关论文
共 50 条
  • [21] TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series
    Toumi, N.
    Ben Kridis, W.
    Mnejja, W.
    Bouzguenda, R.
    Khanfir, A.
    Ghorbel, A.
    Daoud, J.
    Frikha, M.
    CANCER RADIOTHERAPIE, 2018, 22 (03): : 216 - 221
  • [22] Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma
    Wang, Fangzheng
    Jiang, Chuner
    Ye, Zhimin
    Sun, Quanquan
    Liu, Tongxin
    Xu, Min
    Wu, Peng
    Shi, Kaiyuan
    Long, Bin
    Rihito, Aizawa
    Masoto, Sakamoto
    Fu, Zhenfu
    ONCOTARGET, 2017, 8 (43) : 75544 - 75556
  • [23] Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma
    Barone, C.
    Grillo, R.
    Dongiovanni, D.
    Birocco, N.
    Rampino, M.
    Redda, M. G. Ruo
    Garibaldi, E.
    Munoz, F.
    Pecorari, G.
    Cavalot, A.
    Garzinodemo, P.
    Buffoni, L.
    Ciuffreda, L.
    Ricardi, U.
    Cortesina, G.
    Giordano, C.
    Fasolis, M.
    Berrone, S.
    Bertetto, O.
    Schena, M.
    ANTICANCER RESEARCH, 2008, 28 (2B) : 1285 - 1291
  • [24] Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma
    Wang, Qiaoli
    Xu, Guoqiang
    Xia, Yaoxiong
    Zuo, Jia
    Zeng, Guilin
    Xue, Zhihong
    Cao, Ruixue
    Xiong, Wei
    Li, Wenhui
    ORAL ONCOLOGY, 2020, 111
  • [25] Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma
    Golden, D. W.
    Rudra, S.
    Witt, M. E.
    Nwizu, T.
    Cohen, E. E. W.
    Blair, E.
    Stenson, K. M.
    Vokes, E. E.
    Haraf, D. J.
    ORAL ONCOLOGY, 2013, 49 (03) : 277 - 282
  • [26] A real-world study: Induction chemoimmunotherapy versus induction chemotherapy followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma patients with stage IVa
    Wu, K.
    Li, Q.
    Luo, X.
    Wei, X.
    Wang, L.
    Li, Y. -S.
    ANNALS OF ONCOLOGY, 2024, 35
  • [27] Induction chemotherapy in Locally Advanced Nasopharyngeal carcinoma is of benefit?
    Benkhaled, S.
    Mane, M.
    Dragan, T.
    Beauvois, S.
    Lalami, Y.
    Van Gestel, D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 141 : S52 - S53
  • [28] Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
    Tao, Hao-Yun
    Zhan, Ze-Jiang
    Qiu, Wen-Ze
    Liao, Kai
    Yuan, Ya-Wei
    Yuan, Tai-Ze
    Zheng, Rong-Hui
    JOURNAL OF CANCER, 2021, 12 (01): : 18 - 27
  • [29] Sensorineural hearing loss following induction chemotherapy plus concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma
    Atchariyasathian, V.
    Pruegsanusak, K.
    Wongsriwattanakul, S.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2015, 129 (08): : 767 - 772
  • [30] A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma
    Peng, Liang
    Chen, Yu-Pei
    Xu, Cheng
    Tang, Ling-Long
    Chen, Lei
    Lin, Ai-Hua
    Liu, Xu
    Sun, Ying
    Ma, Jun
    ORAL ONCOLOGY, 2018, 86 : 258 - 265